News from Illinois CancerCare

FDA Approves New Treatment

12/3/2019 | Genentech announced the FDA approval of Tecentriq (atezolizumab) in combination with chemotherapy agents Abraxane and Carboplatin for the initial treatment of adults with metastatic non-squamous non-small cell lung cancer. This new treatment has shown to benefit patients by preventing their cancer from worsening over a longer period of time and improving survival.

Illinois CancerCare was one of the first research programs in the nation to offer this clinical trial and enrolled 10 patients! It is through participation in clinical trials that our patients were able to not only benefit from this treatment earlier, but also contribute to this drug combination now being available for all applicable patients.

Research is at the heart of all treatment advances. Illinois CancerCare is committed to bringing our patients the most advanced treatment options available through clinical oncology research.